Effectiveness of Nicorandil for Reperfusion of Acute Myocardial Infarction:A Meta-Analysis
CHEN Qing-jie,YANG Yi-ning,MA Yi-tong,LI Xiao-mei,XIE Xiang,YU Zi-xiang,GUO Hai
2012-01-01
Abstract:Objective To evaluate the effectiveness of nicorandil for reperfusion of acute myocardial infarction(AMI),so as to provide high quality evidence for formulating the rational AMI therapy.Methods Databases including The Cochrane Library(Issue 3,2012),PubMed,EMbase,HighWire,CBM,and CNKI were searched to collect randomized controlled trials(RCTs) on nicorandil in AMI reperfusion published before March 2012.Two reviewers independently screened literature according to the inclusion and exclusion criteria,extracted data,and evaluated the methodological quality of the included studies.Then the meta-analysis was conducted using RevMan5.1 software.Results A total of 11 trials involving 1027 patients were included.The results of meta-analyses showed that: for AMI reperfusion,nicorandil could decrease the non-reflow or slow flow rate(RR=0.34,95%CI 0.19 to 0.61,P=0.0003),improve the left ventricular ejection fraction(MD=5.49,95%CI 4.51 to 6.47,P<0.00001),reduce the left ventricular end-diastolic volume(MD=14.38,95%CI-17.31 to -11.45,P<0.00001),and decrease the incidence of cardiac adverse events(RR=0.34,95%CI 0.25 to 0.46,P<0.00001),readmission rate(RR=0.33,95%CI 0.17 to 0.63,P=0.0008) and mortality rate(RR=0.40,95%CI 0.16 to 0.97,P=0.04).Conclusion Current evidence shows that nicorandil used as an adjuvant for AMI reperfusion can increase coronary microcirculation,improve prognosis,and decrease the incidence of cardiac adverse events,readmission and mortality rate.Due to the limited quality and quantity of the included studies,this conclusion still needs to be further proved by performing more large-scale and high quality RCTs,so we suggest clinician should adopt rational therapies based on patient's conditions.